Regulatory Affairs Specialist

What you would do

• Read agency inquiry letters and corresponding sponsor responses to assess whether replies adequately address regulator questions and concerns
• Evaluate clinical documents for logical consistency, unsupported assertions, and potential reviewer red flags across multiple document sets
• Apply ICH CTD/eCTD standards and regional regulatory expectations to determine whether submissions meet agency requirements
• Write structured, evidence-based feedback highlighting specific regulatory risks and recommending targeted revisions
• Contribute domain expertise in regulatory strategy, flagging issues that might benefit from revised approach rather than minor rewording

Who they want

• 5+ years direct experience with clinical submissions at a sponsor, CRO, or consultancy
• Track record of composing comprehensive responses to regulatory inquiries from health authorities
• Working knowledge of ICH framework, CTD/eCTD structure, and expectations of at least one major agency (FDA, EMA, MHRA, PMDA, Health Canada)
• Ability to critically analyze clinical and safety documents to spot regulatory vulnerabilities and unsupported reasoning
• Strong written communication skills that convey regulatory logic concisely and defensibly

Main skills

What the interview asks about

1. 1.Spotting unsupported regulatory claims

   Reviewers scrutinize every statement; claims without solid backing delay approvals or trigger additional information requests that extend timelines.

   For example: “A sponsor response states 'long-term safety is well-established based on this Phase II study with 40 patients over 12 weeks.' What's missing, and how would you frame this to a regulator?”

2. 2.Identifying consistency failures across documents

   Regulatory submissions are large and complex; contradictions between documents signal either sloppy work or genuine knowledge gaps that regulators will probe.

   For example: “The clinical summary claims a drug is metabolized primarily by hepatic pathways; the pharmacokinetics module states renal excretion predominates. How do you flag this inconsistency in feedback?”

3. 3.Assessing scope creep in submissions

   Sponsors sometimes propose post-approval commitments or study designs that exceed what's feasible or appropriate, creating enforcement risk.

   For example: “A sponsor commits to a five-year post-market surveillance study with 5,000 patients across three continents. Red flags you'd raise in your review?”

4. 4.Recognizing regional regulatory differences

   A response that satisfies FDA may be insufficient for EMA; working knowledge of each region's standards is essential to avoid costly surprises.

   For example: “A sponsor submits an identical response to matching FDA and EMA questions on subgroup analysis. Where might EMA have different expectations than FDA based on their review guidance?”

5. 5.Weighing evidence strength for claims

   Not all data are equally compelling; distinguishing between anecdotal, observational, and rigorous evidence shapes whether regulators accept assertions.

   For example: “A safety claim rests on two published case reports and one post-market adverse event report. How would you assess this evidence in regulatory context, and what additional data might strengthen the argument?”

A task you may get

Review a real or realistic health authority information request and a sponsor draft response, then identify three substantive regulatory gaps (e.g., unsupported claim, missing context, scope issue) with written recommendations for revision.

How to prepare

• Read ICH M3 (Non-Clinical and Clinical Evaluation of Medicinal Products) and ICH Common Technical Document structure to refresh knowledge of required elements
• Find and analyze 2-3 recent FDA advisory committee briefing documents to see what regulators actually question and how strong responses are structured
• Study examples of FDA warning letters or complete response letters to understand what submission deficiencies trigger regulatory action

The facts

Pay

$50–80/hr

Open to

Bangladesh, Hong Kong, India, Indonesia, Japan, Kazakhstan, Kyrgyzstan, Malaysia, Pakistan, Philippines, Singapore, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam, Austria, Belarus, Belgium, Denmark, France, Germany, Greece, Italy, Netherlands, Portugal, Russia, Spain, Switzerland, United Kingdom, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Tunisia, United Arab Emirates, United States, Canada, Nigeria, Kenya, South Africa, Ghana, Ethiopia

Field

Medicine

Role type

Specialist

Posted

8/4/2026

Places left

30

We wrote this page from the public micro1 listing. It may be out of date, so read the full posting before you apply.